Table 1.
Demographics of subjects participating in four studies1 who received anthrax vaccine adsorbed (AVA) subcutaneously at 0, 2 and 4 weeks2.
| Study & group | Number of subjects | Number (%) females | Number (%) Caucasian | Number (%) African-American | Number (%) other race |
|---|---|---|---|---|---|
| Subjects aged 18 to 20 years | |||||
| AVA000 | 14 | 6 | 11 | 3 | 0 |
| AVA005 | 26 | 9 | 21 | 1 | 4 |
| AVA006 | 17 | 8 | 16 | 1 | 0 |
| AVA009 | 17 | 7 | 10 | 7 | 0 |
| Total | 74 | 30 (40.5)2 | 58 (78.4)2 | 12 (16.2)2 | 4 (5.4)2 |
| Subjects aged 21 to 29 years | |||||
| AVA000 | 63 | 31 | 49 | 8 | 6 |
| AVA005 | 56 | 24 | 48 | 4 | 4 |
| AVA006 | 78 | 41 | 68 | 7 | 3 |
| AVA009 | 46 | 24 | 26 | 18 | 2 |
| Total | 243 | 120 (49.4) | 191 (78.6) | 37 (15.2) | 15 (6.2) |
1
AVA000 is a Center for Disease Control and Prevention (CDC) study (Ref. [27]) and AVA005, AVA006, and AVA009 (Refs. [28–30]) are Biomedical Advanced Research and Development Authority (BARDA) funded studies.
2
P-value assessed as not statistically significant by Fisher’s exact test comparing the 18 to 20 and 21 to 29 year old age groups.